STRATEC acquires the BioSciences business from Sony

Sony DADC Austria AG, a leading high-precision optical disc manufacturer, has sold Sony DADC BioSciences GmbH to STRATEC Biomedical AG, Birkenfeld, Germany. The respective purchase agreement was signed on June 8, 2016, based on a company valuation exceeding EUR 30 Mio. The parties expect to complete the transaction during the third quarter 2016 at the latest.

Sony DADC BioSiences is a leading global OEM supplier of smart consumables for diagnostics, life sciences and medical technology applications. The company operates its business with more than 120 employees in a certified production facility in Anif/Austria. The company covers the entire value chain from development and design, production and quality assurance to logistics. Its customers include global players in highly regulated markets.

The purchaser, STRATEC Biomedical AG designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology on the basis of its own patented technologies. The stocks of the company are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index compiled by Deutsche Börse.

TRACC LEGAL, Munich, has comprehensively advised STRATEC during the whole transaction process in legal matters. The legal process was managed by Dr. Thomas Lotz (M&A), assisted by Dr. Thorsten Steinhaus (IP), Matthias Beer and Raoul Steck (Due Diligence).